KTRA vs. OCUP, MLND, ELDN, BTAI, CKPT, MNOV, VHAQ, AFMD, LTRN, and LPTX
Should you be buying Kintara Therapeutics stock or one of its competitors? The main competitors of Kintara Therapeutics include Ocuphire Pharma (OCUP), Millendo Therapeutics (MLND), Eledon Pharmaceuticals (ELDN), BioXcel Therapeutics (BTAI), Checkpoint Therapeutics (CKPT), MediciNova (MNOV), Viveon Health Acquisition (VHAQ), Affimed (AFMD), Lantern Pharma (LTRN), and Leap Therapeutics (LPTX). These companies are all part of the "medical" sector.
Ocuphire Pharma (NASDAQ:OCUP) and Kintara Therapeutics (NASDAQ:KTRA) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, media sentiment, earnings, analyst recommendations, institutional ownership, risk, community ranking, profitability and dividends.
Ocuphire Pharma presently has a consensus price target of $18.75, indicating a potential upside of 983.82%. Given Kintara Therapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe Ocuphire Pharma is more favorable than Kintara Therapeutics.
Ocuphire Pharma has a beta of 0.35, indicating that its share price is 65% less volatile than the S&P 500. Comparatively, Kintara Therapeutics has a beta of 0.7, indicating that its share price is 30% less volatile than the S&P 500.
Kintara Therapeutics has a net margin of 0.00% compared to Kintara Therapeutics' net margin of -59.44%. Ocuphire Pharma's return on equity of 0.00% beat Kintara Therapeutics' return on equity.
In the previous week, Ocuphire Pharma and Ocuphire Pharma both had 1 articles in the media. Kintara Therapeutics' average media sentiment score of 0.00 equaled Ocuphire Pharma'saverage media sentiment score.
Ocuphire Pharma has higher revenue and earnings than Kintara Therapeutics. Ocuphire Pharma is trading at a lower price-to-earnings ratio than Kintara Therapeutics, indicating that it is currently the more affordable of the two stocks.
15.0% of Ocuphire Pharma shares are owned by institutional investors. Comparatively, 0.6% of Kintara Therapeutics shares are owned by institutional investors. 8.7% of Ocuphire Pharma shares are owned by insiders. Comparatively, 0.2% of Kintara Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Ocuphire Pharma received 18 more outperform votes than Kintara Therapeutics when rated by MarketBeat users. However, 88.89% of users gave Kintara Therapeutics an outperform vote while only 68.00% of users gave Ocuphire Pharma an outperform vote.
Summary
Ocuphire Pharma beats Kintara Therapeutics on 11 of the 16 factors compared between the two stocks.
Get Kintara Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for KTRA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding KTRA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Kintara Therapeutics Competitors List
Related Companies and Tools
